{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:49:03Z","timestamp":1777988943438,"version":"3.51.4"},"posted":{"date-parts":[[2026,2,6]]},"group-title":"Molecular Biology","reference-count":58,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Novel antiviral approaches capable of permanently inactivating the intrahepatic HBV DNA reservoir, the covalently closed circular DNA (cccDNA) and HBV DNA integrated into the host genome, are urgently needed. This study evaluated adenine base editing as a strategy to disrupt HBV replication by introducing mutations in the overlapping HBs\/polymerase open reading frame (ORF).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An adenine base editor (ABE) and 3 guide RNAs (gS1-gS3) were designed to introduce missense mutations within the HBs\/polymerase ORF. ABE mRNA and individual gRNAs were co-transfected into HBV-infected HepG2-hNTCP cells and primary human hepatocytes. Antiviral efficacy was further assessed in HepG2.2.15 and PLC\/PRF\/5 cells harboring integrated HBV DNA. In vivo, lipid nanoparticles (LNP)-mediated delivery of ABE mRNA and gRNAs was evaluated in HBVcircle DNA-transduced mice and in HBV-infected human liver-chimeric mice. The impact of HBs editing on hepatitis D virus (HDV) release was assessed using PLC\/PRF\/5 and Huh7 cell-based HDV replication models.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Adenine base editing efficiently reduced HBsAg production and HBV replication in vitro by targeting both cccDNA and integrated HBV DNA. A single LNP injection of ABE-gS2 resulted in undetectable HBsAg in HBVcircle mice, while two injections achieved a 90% reduction in serum HBsAg in HBV-infected human liver chimeric mice. HBV DNA replication was also inhibited in vivo. Furthermore, HBs ORF base editing markedly suppressed HDV release in vitro.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adenine base editing of the HBs ORF effectively impairs HBV replication and HBsAg production in vitro and in vivo and concomitantly inhibits HDV release, highlighting its therapeutic potential.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.06.704371","type":"posted-content","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:10:19Z","timestamp":1770433819000},"source":"Crossref","is-referenced-by-count":0,"title":["Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-8012","authenticated-orcid":false,"given":"Anuj","family":"Kumar","sequence":"first","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-6615","authenticated-orcid":false,"given":"Emmanuel","family":"Combe","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena M","family":"Smekalova","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selam","family":"Dejene","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Leboeuf","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Mougen\u00e9","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Deleume","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-8480","authenticated-orcid":false,"given":"Caroline","family":"Scholtes","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"},{"name":"Lyon 1 Universit\u00e9, Service de Virologie, Hospices Civils de Lyon (HCL), 69004 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-4586","authenticated-orcid":false,"given":"Marie-Laure","family":"Plissonnier","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0611-7257","authenticated-orcid":false,"given":"Xavier","family":"Grand","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7236-2911","authenticated-orcid":false,"given":"Maria G","family":"Martinez","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ciaramella","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Gregoire","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Packer","sequence":"additional","affiliation":[{"name":"Beam Therapeutics, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5588-5465","authenticated-orcid":false,"given":"Barbara","family":"Testoni","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[{"name":"UMR U1350, Pathobiology and Therapy of Liver Diseases (PaThLiv); INSERM, Lyon 1 University, Lyon, France"},{"name":"The Lyon Hepatology Institute, IHU EVEREST, 69003 Lyon, France"},{"name":"Department of Hepatology, Hospices Civils de Lyon (HCL), 69004 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026021008112381000_2026.02.06.704371v1.1","doi-asserted-by":"crossref","first-page":"e0001424","DOI":"10.1128\/mmbr.00014-24","article-title":"Hepatitis B virus entry, assembly, and egress","volume":"88","year":"2024","journal-title":"Microbiol Mol Biol Rev"},{"key":"2026021008112381000_2026.02.06.704371v1.2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg < 100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","year":"2021","journal-title":"J Gastroenterol"},{"key":"2026021008112381000_2026.02.06.704371v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.014"},{"key":"2026021008112381000_2026.02.06.704371v1.4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a Functional Cure for Hepatitis B","volume":"18","year":"2024","journal-title":"Gut Liver"},{"key":"2026021008112381000_2026.02.06.704371v1.5","doi-asserted-by":"crossref","unstructured":"Zheng J , Wang Z , Huang L , Qiu Z , Xie Y , Jiang S , et al. Achieving chronic hepatitis B functional cure: Factors and potential mechanisms. Virus Res. 2025;351:199507.","DOI":"10.1016\/j.virusres.2024.199507"},{"key":"2026021008112381000_2026.02.06.704371v1.6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3390\/biom13081208","article-title":"Chronic Hepatitis B Infection: New Approaches towards Cure","volume":"13","year":"2023","journal-title":"Biomolecules"},{"key":"2026021008112381000_2026.02.06.704371v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00724-5"},{"key":"2026021008112381000_2026.02.06.704371v1.8","doi-asserted-by":"crossref","unstructured":"Hui RW-H , Mak L-Y , Seto W-K , Yuen M-F . Investigational RNA Interference Agents for Hepatitis B. BioDrugs. 2024;","DOI":"10.1007\/s40259-024-00694-x"},{"key":"2026021008112381000_2026.02.06.704371v1.9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2024.05.025","article-title":"CRISPR-Cas13b-mediated suppression of HBV replication and protein expression","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"2026021008112381000_2026.02.06.704371v1.10","doi-asserted-by":"crossref","unstructured":"Hui RW-H , Mak L-Y , Fung J , Seto W-K , Yuen M-F . Prospect of emerging treatments for HBV functional cure. Clin Mol Hepatol. 2024;","DOI":"10.3350\/cmh.2024.0855"},{"issue":"Suppl 1","key":"2026021008112381000_2026.02.06.704371v1.11","first-page":"87","article-title":"Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity","volume":"43","year":"2023","journal-title":"Liver Int"},{"key":"2026021008112381000_2026.02.06.704371v1.12","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/v14122654","article-title":"Gene Editing Technologies to Target HBV cccDNA","volume":"14","year":"2022","journal-title":"Viruses"},{"key":"2026021008112381000_2026.02.06.704371v1.13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/v16101565","article-title":"Applications of CRISPR\/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics","volume":"16","year":"2024","journal-title":"Viruses"},{"key":"2026021008112381000_2026.02.06.704371v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.013"},{"key":"2026021008112381000_2026.02.06.704371v1.15","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2021.0120"},{"key":"2026021008112381000_2026.02.06.704371v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09006-2"},{"key":"2026021008112381000_2026.02.06.704371v1.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-023-02561-1"},{"key":"2026021008112381000_2026.02.06.704371v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0918-899c"},{"key":"2026021008112381000_2026.02.06.704371v1.19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s12015-024-10715-5","article-title":"Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases","volume":"20","year":"2024","journal-title":"Stem Cell Rev Rep"},{"key":"2026021008112381000_2026.02.06.704371v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0059-1"},{"key":"2026021008112381000_2026.02.06.704371v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.045"},{"key":"2026021008112381000_2026.02.06.704371v1.22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent Inactivation of HBV Genomes by CRISPR\/Cas9-Mediated Non-cleavage Base Editing","volume":"20","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026021008112381000_2026.02.06.704371v1.23","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep4.1933","article-title":"Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing","volume":"6","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026021008112381000_2026.02.06.704371v1.24","doi-asserted-by":"crossref","unstructured":"Smekalova EM , Martinez MG , Combe E , Kumar A , Dejene S , Leboeuf D , et al. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo. Mol Ther Nucleic Acids. 2024;35:102112.","DOI":"10.1016\/j.omtn.2023.102112"},{"key":"2026021008112381000_2026.02.06.704371v1.25","doi-asserted-by":"crossref","unstructured":"Qin B , Shen S , Chen H , Wang Y , Ding J , Ding J . Inactivation of the key ORFs of HBV for antiviral therapy by non-cleavage base editing. Microb Pathog. 2025;205:107689.","DOI":"10.1016\/j.micpath.2025.107689"},{"key":"2026021008112381000_2026.02.06.704371v1.26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.omtn.2020.06.019","article-title":"Large-Fragment Deletions Induced by Cas9 Cleavage while Not in the BEs System","volume":"21","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026021008112381000_2026.02.06.704371v1.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9973"},{"key":"2026021008112381000_2026.02.06.704371v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0414-6"},{"key":"2026021008112381000_2026.02.06.704371v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1161-z"},{"key":"2026021008112381000_2026.02.06.704371v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15887-5"},{"key":"2026021008112381000_2026.02.06.704371v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0491-6"},{"key":"2026021008112381000_2026.02.06.704371v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0453-z"},{"key":"2026021008112381000_2026.02.06.704371v1.33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05957-3"},{"key":"2026021008112381000_2026.02.06.704371v1.34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021008112381000_2026.02.06.704371v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00933-4"},{"key":"2026021008112381000_2026.02.06.704371v1.36","unstructured":"Chen Delai . Using Base Editing and LNP Delivery to Correct Disease-Causing Mutations Underlying Genetic Liver Diseases [Internet]. Washington: Available from: https:\/\/beamtx.com\/wp-content\/uploads\/2021\/05\/Using-Base-Editing-and-LNP-Delivery-to-Correct-Disease-Causing-Mutations-Underlying-Genetic-Liver-Diseases.pdf"},{"key":"2026021008112381000_2026.02.06.704371v1.37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.63.5.1945-1950.1989"},{"key":"2026021008112381000_2026.02.06.704371v1.38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00430-14"},{"key":"2026021008112381000_2026.02.06.704371v1.39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.68.6.4063-4066.1994"},{"key":"2026021008112381000_2026.02.06.704371v1.40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1022"},{"key":"2026021008112381000_2026.02.06.704371v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.07.014"},{"key":"2026021008112381000_2026.02.06.704371v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.02.004"},{"key":"2026021008112381000_2026.02.06.704371v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.040"},{"key":"2026021008112381000_2026.02.06.704371v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0032-3"},{"key":"2026021008112381000_2026.02.06.704371v1.45","first-page":"e01416","article-title":"Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro","volume":"92","year":"2018","journal-title":"J Virol"},{"issue":"24","key":"2026021008112381000_2026.02.06.704371v1.46","first-page":"02343","article-title":"Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"S0168-8278","year":"2024","journal-title":"J Hepatol"},{"key":"2026021008112381000_2026.02.06.704371v1.47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/v11030263","article-title":"Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection","volume":"11","year":"2019","journal-title":"Viruses"},{"key":"2026021008112381000_2026.02.06.704371v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644"},{"key":"2026021008112381000_2026.02.06.704371v1.49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062132"},{"key":"2026021008112381000_2026.02.06.704371v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03534-y"},{"key":"2026021008112381000_2026.02.06.704371v1.51","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.0c00638","article-title":"HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection","volume":"7","year":"2021","journal-title":"ACS Infect Dis"},{"key":"2026021008112381000_2026.02.06.704371v1.52","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.032"},{"key":"2026021008112381000_2026.02.06.704371v1.53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.11.056"},{"key":"2026021008112381000_2026.02.06.704371v1.54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/v13050777","article-title":"Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions","volume":"13","year":"2021","journal-title":"Viruses"},{"key":"2026021008112381000_2026.02.06.704371v1.55","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-01030-y"},{"key":"2026021008112381000_2026.02.06.704371v1.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.035"},{"key":"2026021008112381000_2026.02.06.704371v1.57","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.dld.2025.01.022","article-title":"HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA","volume":"57","year":"2025","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 1","key":"2026021008112381000_2026.02.06.704371v1.58","first-page":"11","article-title":"Hepatitis delta virus: Disease assessment and stratification","volume":"30","year":"2023","journal-title":"J Viral Hepat"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.06.704371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:11:37Z","timestamp":1770739897000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.02.06.704371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":58,"URL":"https:\/\/doi.org\/10.64898\/2026.02.06.704371","relation":{"has-review":[{"id-type":"doi","id":"10.1162\/2e3983f5.7774d5d3","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.3090480a","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.44ad511d","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.facf168b","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2026,2,6]]},"subtype":"preprint"}}